Daykin Harriet
North Devon District Hospital, Barnstaple, UK.
Br J Pain. 2017 Feb;11(1):23-31. doi: 10.1177/2049463716676205. Epub 2016 Oct 24.
Opioids remain the mainstay of analgesia for the treatment of moderate to severe acute pain. Even in the young, the use of opioids can be associated with an increased incidence of post-operative complications such as respiratory depression, vomiting, pruritus, excessive sedation, slowing of gastrointestinal function, and urinary retention. The need to manage acute pain in the older patient is becoming more common as the population ages, and increasingly older patients are undergoing more major surgery. Medical conditions are more common in older people and can result in the requirement of systemic analgesia for fractures, malignancy, nociceptive or neuropathic pain and peripheral vascular disease. Effective pain control can be difficult in older patients as there is a higher incidence of coexistent diseases, polypharmacy and age-related changes in physiology, pharmacodynamics and pharmacokinetics. Consequently, due to the fear of respiratory depression in older people, this leads to inadequate doses of opioid being given for the treatment of their pain. Lidocaine has analgesic, anti-hyperalgesic and anti-inflammatory properties and is metabolized by the liver which is limited by perfusion, and heart failure or drugs can alter this, affecting its clearance. Therefore, there are concerns regarding safety in older patients as plasma concentrations have both intersubject and intrasubject variability. The aim of this literature review is to assess the efficacy and safety of intravenous lidocaine as an adjuvant in pain management for the older patient. In total, 12 studies fulfilled the criteria. Lidocaine infusions were found to reduce pain scores and be opioid sparing in abdominal and urological surgery, in patients with opioid-refractory malignancy pain, neuropathic pain and critical limb ischaemia. Patients with malignancy were more likely to develop adverse effects, but no patients required treatment for lidocaine toxicity.
阿片类药物仍然是治疗中度至重度急性疼痛的主要镇痛药物。即使在年轻人中,使用阿片类药物也可能与术后并发症的发生率增加有关,如呼吸抑制、呕吐、瘙痒、过度镇静、胃肠功能减慢和尿潴留。随着人口老龄化,老年患者急性疼痛管理的需求越来越普遍,越来越多的老年患者正在接受更大型的手术。老年人的疾病更为常见,可能需要对骨折、恶性肿瘤、伤害性或神经性疼痛以及外周血管疾病进行全身镇痛。老年患者有效控制疼痛可能很困难,因为并存疾病、多种药物治疗以及生理、药效学和药代动力学方面与年龄相关的变化发生率更高。因此,由于担心老年人出现呼吸抑制,这导致用于治疗其疼痛的阿片类药物剂量不足。利多卡因具有镇痛、抗痛觉过敏和抗炎特性,由肝脏代谢,而肝脏代谢受灌注限制,心力衰竭或药物可改变这种情况,影响其清除率。因此,由于血浆浓度存在个体间和个体内变异性,老年患者的安全性受到关注。这篇文献综述的目的是评估静脉注射利多卡因作为老年患者疼痛管理辅助药物的疗效和安全性。总共有12项研究符合标准。在腹部和泌尿外科手术、阿片类药物难治性恶性肿瘤疼痛、神经性疼痛和严重肢体缺血患者中,发现利多卡因输注可降低疼痛评分并减少阿片类药物用量。恶性肿瘤患者更有可能出现不良反应,但没有患者因利多卡因毒性需要治疗。